Pasithea Therapeutics Corp. received a letter from Nasdaq on August 20, 2026, granting a 180-day extension until February 16, 2027, to regain compliance with the minimum bid price requirement of $1.00 per share. The company was previously notified in February 2026 that its stock had failed to maintain this threshold for 30 consecutive business days and had an initial grace period ending August 19, 2026. Pasithea may consider implementing a reverse stock split or other options to regain compliance but cannot assure success; failure to comply could result in delisting subject to appeal. The company operates in the biotechnology industry, focusing on drug discovery and development.